We have characterized the biodistribution and dosimetry of 18 F-39-F-6-OH-BTA1 ( 18 F-GE067), a newly developed radioligand to visualize and quantify amyloid burden, in healthy elderly human subjects. Methods: Six subjects (5 men and 1 woman; age range, 51-74 y) underwent dynamic whole-body PET/CT for 6 h after a bolus injection of 18 F-GE067. Source organs were delineated on PET/CT. Individual organ doses and effective doses were determined. Results: No adverse events or clinically significant changes were observed. 18 F-GE067 is excreted predominantly through the hepatobiliary system. The gallbladder, upper large intestine, and small intestine are the organs with the highest absorbed dose (average, 287, 173, and 155 mGy/ MBq, respectively). The mean effective dose was 33.8 6 3.4 mSv/MBq, a dose comparable to that of many other 18 F-labeled radiopharmaceuticals. Conclusion: The estimated effective dose of 18 F-GE067 for PET amyloid imaging was acceptable (class II-b defined by the World Health Organization), and relatively low variability between subjects was observed.
Al zheimer disease (AD) affects 7% of the general population older than 65 y and 30% of those older than 80 y (1) . According to a meta-analysis of a prospective clinicopathologic series conducted in academic memory clinics, the sensitivity of a diagnosis of clinically probable AD is 0.65 (60.15 SD) and specificity is 0.76 (60.20). If clinically probable and possible AD are combined, the sensitivity is 0.90 (60.07), but specificity drops to 0.56 (60.22) (2) . It has been proposed that, at least in the setting of clinical research studies and drug development, biomarkers such as the imaging of amyloid b (Ab) by PET and cerebrospinal fluid analysis of Ab and tau proteins should be included in new diagnostic criteria for AD, to increase the accuracy and allow earlier interventions of disease-modifying strategies (3) .
In vivo imaging of Ab in the brain using PET and SPECT has been successful with 11 C-labeled compounds such as 11 C-Pittsburgh compound B ( 11 C-PIB) (4), 11 C-4-N-methylamino-49-hydroxystilbene (5), and 11 C-2-(2-[2-dimethylaminothiazol-5-yl]ethenyl)-6-(2-[fluoro]ethoxy)benzoxazole (6) but less so with 123 I-labeled compounds such as 123 I-6-iodo-2-(49-dimethylamino-)phenyl-imidazo[1,2-a]pyridine ( 123 I-IMPY) (7) . 11 C-PIB shows a 2-fold increase in cortical signal in probable AD patients versus controls, and neuropathologic studies have confirmed that regional 11 C-PIB binding in vivo correlates with levels of Ab measured after death (8) . However, only a few centers equipped with an on-site cyclotron are able to perform 11 C-based ligand studies. 18 Fbased amyloid imaging agents would make in vivo imaging of Ab more available for routine clinical use and allow longitudinal studies across multiple centers. So far, four 18 F-labeled ligands for use in humans are being developed. 18 
is a naphthol, which labels both plaques and tangles in the brain but has a low specific signal (9) . 18 F-4-(N-methylamino)-49-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy) stilbene and 18 F-AV45 are stilbene derivatives, selective for Ab, and show an uptake pattern similar to 11 C-PIB (10).
Here we have characterized the safety, biodistribution, and radiation dosimetry of a novel 18 F-labeled benzothiazole compound selective for human Ab, 18 F-39-F-6-OH-BTA1 ( 18 F-GE067), a structural thioflavin analog of 11 C-PIB, in a study involving 6 healthy elderly human subjects. 18 F-GE067 allows in vivo PET of amyloid deposits in the AD brain (N. Nelissen, K. Van Laere, L. Thurfjell, et al., unpublished data, 2009).
MATERIALS AND METHODS

Healthy Subjects
Healthy subjects were recruited as part of a phase I PET study sponsored by GE Healthcare Ltd. and in response to an adver-tisement in a local community newspaper. Six healthy Caucasian subjects (5 men; 1 woman; age range, 51-74 y) were included in the study. Demographic data for these subjects are summarized in Table 1 . The subjects did not have any clinically significant medical or neurologic condition, and they did not have any clinically significant abnormality on physical, neurologic, or laboratory examinations. In addition, they did not have a first-degree relative with a diagnosis of AD. The study was approved by the local Ethics Committee, and written informed consent was obtained from all the volunteers before the study started.
Radiotracer Characteristics and Preparation
The investigational medicinal product 18 F-GE067 was batchmanufactured according to Good Manufacturing Guidelines, Eudralex volume 4, Annex 3 (11), at the Cyclotron Research Centre, University of Liege, Belgium, using a TracerLab-FX F-N (GE Healthcare) chemistry platform. The chemical and radiochemical purity of the test item was assessed by analytic highperformance liquid chromatography system equipped with an ultraviolet and radioactivity detector. The total unlabeled GE067 chemical content was 0.7 6 0.3 mg/mL, and the radiochemical purity was 98.1% 6 1.2%. The identity of the radiolabeled product was confirmed by coelution on high-performance liquid chromatography of a cold analytic standard of GE067. 18 F-GE067 was supplied as a ready-to-inject solution with a maximum of 10 mg of cold GE067 per dose; the solution for injection contained 7% ethanol (v/v) and 0.5% polysorbate 80 (w/v) in phosphate buffer (0.015 M).
PET/CT Procedure
Subjects received on average 121 MBq (range, 96-147 MBq) of 18 F-GE067 as a slow intravenous bolus injection (;10 s) through a catheter in an antecubital vein. A dynamic series of whole-body PET emission scans was obtained as described previously (12) .
All subjects were scanned with a PET/CT camera (HiRez Biograph16; Siemens) at 3 consecutive times. For the first 90 min, 8 sequential whole-body scans from the midfemoral position to the head were obtained. During the other 2 times, single whole-body scans were obtained at about 160 and 260 min after injection. A lowdose (tube potential, 80 kV; effective mAs, 11), no-contrast, wholebody CT scan was obtained at the beginning of each time. The additional radiation burden of this low-dose CT was 0.5 mSv per whole-body scan.
Urine samples were collected and counted between scanning times, up to 6 h after injection (n 5 5/subject).
Images from the HiRez Biograph16 were reconstructed using a 3-dimensional ordered-subset expectation maximization iterative algorithm (5 iterations and 8 subsets) and postsmoothed with a 3-dimensional gaussian filter (6-mm full width at half maximum). Reconstruction included model-based scatter as well as attenuation correction based on the measured CT-attenuation map.
Volumes of Interest (VOI)
Data transfer, VOI definition, and processing to calculate timeactivity curves were performed as described previously using PMOD software (version 2.9; PMOD Inc.) (12) . The following organs showed significant tracer accumulation and were included in the VOI template: brain, gallbladder, small intestine, heart, kidneys, liver, lungs, axial bone marrow, spleen, thyroid, and urinary bladder.
Residence Time and Absorbed Dose Calculations
Residence times were computed and normalized to injected activities by calculating the area under the time-activity curve of each organ. This was done using curve fitting to the time-activity curves as the primary method. The uptake in the brain, heart, liver, kidneys, red marrow, lungs, spleen, and remainder could be modeled with the following function:
2 expð2lnð2Þ · t=t u;i ÞÞ · expð2lnð2Þ · t=t e;i Þ;
where i 5 1-3, A i was a scaling parameter, t u,i represented the uptake time parameters, and t e,i represented the excretion time parameters. The model was fitted to the data by least-squares constraint minimization. Small intestine time-activity curves for 2 subjects and the gallbladder and thyroid time-activity curves in all subjects were not satisfactorily described by kinetic modeling. The curve fitting for these subjects and organs did not converge to an acceptable solution, even by changing the start estimates over a large representative range. For the intestine, accumulated activity entering the intestines at the last 2 times did not approximate the final fraction closely enough for unique fitting solutions. For the gallbladder, large variability in the measured values was encountered. In these subjects and organs, values based on the trapezoid rule were used, and the area under the curve after the acquisition of the last image was calculated by assuming only physical decay of 18 F and no additional biologic clearance to be conservative. Previously, we have shown that the calculation of the area under the curve using the trapezoid method gives a good approximation of the residence time (12) .
The absorbed doses reported were calculated using OLINDA (Vanderbilt University), and the effective dose (ED) was calculated from the individual organ doses on the basis of a predefined weighting factor for each of the source organs (13).
The residence times for the upper large intestine (ULI), lower large intestine (LLI), and small intestine were calculated in 2 ways. For the 4 subjects in whom the fraction of injected activity entering the small intestine could be estimated accurately, we used the International Commission on Radiological Protection (ICRP) 30 (14) gastrointestinal model as incorporated in OLINDA, using the fraction entering the small intestine as input (calculated from the kinetic modeling of the intestinal VOI time-activity curves). This value was set equal to the largest decay-corrected fraction of injected activity encompassed by the intestinal region of interest. For the 2 subjects in whom no accurate estimate of the fraction injected activity could be made, we also used a predefined distribution of residence times-50% for the small intestine, 25% for the ULI, and 25% for the LLI-which is a good approximation for slowly excreted tracers (12) . For the 4 subjects in whom small, ULI, and LLI parameter fitting was possible, the average retention time calculated with the trapezoid method was slightly lower than the kinetically modeled values and resulted in ED estimates that were 5% lower, indicating that the trapezoid approach is appropriate for quantifying organ 18 F-GE067 uptake.
The updated dynamic bladder model (13) was used to calculate dose to the bladder wall, with a bladder voiding interval of 2 h. The fraction of activity excreted through the bladder and the corresponding biologic half-life were based on the accumulated activity excreted at all voiding moments between and after scans. For this purpose A · (1 2 exp(2ln(2) · t/t u )) was fitted to the cumulative activity values, where t u was the biologic decay and A was the fraction of activity released from the body during voiding between scan sequences.
RESULTS
During these studies, no adverse events were reported. All monitored clinical parameters (heart rate, blood pressure, respiration rate, body temperature, 12-lead electrocardiogram) stayed normal during and after scanning. No clinically significant adverse experiences were reported by the subjects at the time of scanning, nor were any reported during the follow-up phone interview 24 h after the scan. Figure 1 shows an exemplary series of whole-body slices of 18 F-GE067 over time for subject 1 ( Table 1 ). The tracer is readily taken up in the brain and liver and quickly excreted in the gastrointestinal system. Urinary tract activity is noted after a few minutes. Figure 2 shows slices through the brain of a representative healthy subject and a patient with AD from the subsequent phase I study with 18 F-GE067.
Supplemental Table 1 (supplemental materials are available online only at http://jnm.snmjournals.org) shows calculated residence times. The highest variability in residence times was observed for the small intestine and gallbladder. The mean residence time for the gallbladder for all subjects was 0.16 6 0.011 h, with the lowest value of 0.014 h and the highest value 0.312 h. Figure 3 shows decay-corrected relative time-activity curves for the brain, liver, small intestine, gallbladder, and urinary bladder after injection of 18 F-GE067. Up to 20% of the injected activity is excreted through the urinary tract; the remainder is eliminated through the gastrointestinal tract. Table 2 summarizes the individual organ doses and individual ED results for all subjects and the means and SD. The gallbladder wall is the dose-limiting organ, with the highest organ dose of 0.287 mGy/MBq. For a standard injected activity of 185 MBq, no individual organ dose would, therefore, exceed 200 mGy. A high variability in the gallbladder organ-absorbed dose, between 0.051 and 0.520 mGy/MBq (SD, 0.164 mGy/MBq), was observed. Table 1 includes the individual ED estimates for all subjects. The average ED was 33.8 mSv/MBq (range, 29.4-37.5 mSv/MBq). No significant difference in ED was found between the 5 men and 1 woman in the study, and no changes were observed within the small age range of participating subjects.
DISCUSSION
Our dosimetry studies on 18 F-GE067 have resulted in an ED estimate for the tracer of 33.8 mSv/MBq. The subjects participating in this study received a total ED of 4.12 6 0.96 mSv for the PET and 1.5 mSv for the CT parts. Compared with other 18 F-labeled radiopharmaceuticals with typical ED values in the range of 20-35 mSv/MBq, 18 F-GE067 has a radiation burden in the upper range.
The observed distribution pattern of 18 F-GE067 shows predominant hepatobiliary excretion and is similar to that observed for its structural analog 11 C-PIB, with a nearidentical fraction (;20%) of urinary excretion (estimated ED for 11 C-PIB, 4.7 6 0.8 mSv/MBq) (15) . Another human study in 6 subjects by O'Keefe et al. (16) found comparable values resulting in an ED estimate of 5.3 mSv/MBq. Our own measurement in 2 healthy male subjects (age, 20-30 y) (K. Van Laere, written communication, local ethics committee approval report, 2006), using the same methodology as is used in the current work, resulted in 4.8 mSv/MBq. This result confirmed that over various centers, dosimetry estimates are consistent despite some methodologic differences in source organ determination and delineation and indicated that current values for 18 F-GE067 are robust, despite some reports having warned for methodologic differences in determination of and assumptions concerning source organ residence time distribution that may give rise to appreciable differences (17) .
The dosimetry of 18 F-BAY94-9172 in 3 subjects has been described in abstract form by O'Keefe et al. and was low for an 18 F-labeled ligand: 14.7 6 1.4 mSv/MBq (16). Internal dosimetry data for 18 F-FDDNP in humans are not available in the literature at this point. Radiation burden per injected activity for 123 I-IMPY is higher than for the 18 F ligands, with an estimated ED of 42 mSv/MBq (18) .
Although the current estimates were obtained in elderly cognitively intact healthy subjects, none of whom showed evidence of specific increased brain uptake levels indicating amyloid deposition (which has been found in 20%230% of healthy elderly populations (19, 20) ), these data can be extrapolated to pathologic brains. Assuming a conservative 3-fold brain uptake (as a maximum value of the specific uptake increase observed in AD cases) (N. Nelissen, K. Van Laere, L. Thurfjell, et al., unpublished data, 2009) and corresponding increase in residence time for the brain, with unaltered tracer whole-body distribution and excretion, we calculated the influence on total ED. This assumption would augment the ED estimate by less than 1%, to 34.0 mSv/MBq, because the brain is incorporated in the remainder of the body and does not contribute significantly to the ED. Without medication effects that would induce altered hepatic metabolization of the tracer (e.g., enzyme FIGURE 2. Brain uptake distribution of 18 F-GE067 in healthy 64-y-old male subject (top), compared with 68-yold male AD patient (bottom). Transverse, sagittal, and coronal sections indicate absence of specific gray matter uptake of 18 F-GE067 and aspecific uptake in white matter, pons, and thalamus. Images represent standardized uptake value ratios (SUVR) to cerebellar cortex, between 85 and 105 min after injection, obtained from phase I clinical study. FIGURE 3. Mean activity in brain, gallbladder, intestine, liver, and urinary bladder as fraction of total-body activity, at all time points for 6 subjects. induction), the ED calculation is, thus, also valid for patient populations with mild cognitive impairment and AD.
The gallbladder wall was the dose-limiting organ, and a large variability in gallbladder activity was found due to large differences in the individual kinetics of gallbladder emptying, a process influenced by multiple hormonal factors and gastrointestinal interactions.
The average injected tracer mass dose in this study was 10 mg of 18 F-GE067 and did not produce any subjective or clinically meaningful changes in laboratory blood tests, blood pressure, pulse, and respiration rate in any subject. No adverse events were reported in this study. Therefore, in this pilot study 18 F-GE067 also appears to be safe from a pharmacologic standpoint. In view of the limited number of investigated subjects in the current study, further safety data will be collected during the development of the radiopharmaceutical for regulatory submission.
CONCLUSION
The administration of 18 F-GE067 is safe and leads to a reasonable radiation burden to investigated subjects. This result is quantitatively in line with the results of many other 18 F-labeled radioligand studies and thus falls into an ICRP/ World Health Organization class II-b category for standard injected activity (185 MBq or less in view of the more than sufficient image quality) in central nervous system imaging to determine amyloid load in the brain. 
